Reference : Comment je traite… Le mésothéliome pleural malin en 2019.
Scientific journals : Article
Human health sciences : Cardiovascular & respiratory systems
http://hdl.handle.net/2268/257113
Comment je traite… Le mésothéliome pleural malin en 2019.
French
[en] How I manage... Malignant pleural mesothelioma in 2019
PELLEGRINI, Ivan [Centre Hospitalier Universitaire de Liège - CHU > > Service de pneumologie - allergologie >]
SIBILLE, Anne mailto [Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de pneumologie - allergologie >]
PAULUS, Astrid mailto [Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de pneumologie - allergologie >]
VAILLANT, Frédérique mailto [Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de pneumologie - allergologie >]
Radermecker, Maurice [Université de Liège - ULiège > > Relations académiques et scientifiques (Médecine) >]
Corhay, Jean-Louis mailto [Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques >]
Louis, Renaud mailto [Université de Liège - ULiège > Département des sciences cliniques > Pneumologie - Allergologie >]
DUYSINX, Bernard mailto [Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Oncologie thoracique >]
2019
Revue medicale de Liege
74
12
627-632
Yes
National
0370-629X
Belgium
[en] Antineoplastic Combined Chemotherapy Protocols ; Bevacizumab ; Combined Modality Therapy ; Humans ; Mesothelioma/drug therapy ; Pemetrexed ; Pleural Neoplasms/drug therapy ; Immunotherapy ; Mesothelioma ; Radiotherapy ; Surgery ; Chemotherapy
[en] Malignant pleural mesothelioma is a rare disease originating from mesothelial cells of the pleura and is related to asbestos exposure. The tumor is generally extended at the time of diagnosis and the treatment consists of a systemic palliative therapy. Radical approach is limited to very selected patients and is performed in expert centers but without validated schema. Radiotherapy alone is mainly used in palliative intent. Platinum-based chemotherapy in association with pemetrexed is the frontline standard of care and provides a 12-month overall survival. The addition of bevacizumab, an antiangiogenic drug, shows an improvement in median survival. To date, there is no second-line treatment approved for this disease and therefore inclusion in trials is recommended. Currently, various studies are investigating target therapy, immunotherapy and intrapleural perioperative treatment.
http://hdl.handle.net/2268/257113

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
PELLEGRINI 2019_Mésothéliome pleural_RMLG-ppediteur.pdfPublisher postprint259.58 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.